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ABSTRACT New antimalarial drugs are needed. The benzoxaborole AN13762 showed
excellent activity against cultured Plasmodium falciparum, against fresh Ugandan P. falci-
parum isolates, and in murine malaria models. To gain mechanistic insights, we selected
in vitro for P. falciparum isolates resistant to AN13762. In all of 11 independent selections
with 100 to 200 nM AN13762, the 50% inhibitory concentration (IC50) increased from
18–118 nM to 180–890 nM, and whole-genome sequencing of resistant parasites dem-
onstrated mutations in prodrug activation and resistance esterase (PfPARE). The intro-
duction of PfPARE mutations led to a similar level of resistance, and recombinant PfPARE
hydrolyzed AN13762 to the benzoxaborole AN10248, which has activity similar to that of
AN13762 but for which selection of resistance was not readily achieved. Parasites further
selected with micromolar concentrations of AN13762 developed higher-level resistance
(IC50, 1.9 to 5.0M), and sequencing revealed additional mutations in any of 5 genes, 4
of which were associated with ubiquitination/sumoylation enzyme cascades; the intro-
duction of one of these mutations, in SUMO-activating enzyme subunit 2, led to a simi-
lar level of resistance. The other gene mutated in highly resistant parasites encodes the
P. falciparum cleavage and specificity factor homolog PfCPSF3, previously identified as
the antimalarial target of another benzoxaborole. Parasites selected for resistance to
AN13762 were cross-resistant with a close analog, AN13956, but not with standard anti-
malarials, AN10248, or other benzoxaboroles known to have different P. falciparum tar-
gets. Thus, AN13762 appears to have a novel mechanism of antimalarial action and mul-
tiple mechanisms of resistance, including loss of function of PfPARE preventing
activation to AN10248, followed by alterations in ubiquitination/sumoylation pathways
or PfCPSF3.
IMPORTANCE Benzoxaboroles are under study as potential new drugs to treat malaria.
One benzoxaborole, AN13762, has potent activity and promising features, but its mecha-
nisms of action and resistance are unknown. To gain insights into these mechanisms, we
cultured malaria parasites with nonlethal concentrations of AN13762 and generated par-
asites with varied levels of resistance. Parasites with low-level resistance had mutations
in PfPARE, which processes AN13762 into an active metabolite; PfPARE mutations pre-
vented this processing. Parasites with high-level resistance had mutations in any of a
number of enzymes, mostly those involved in stress responses. Parasites selected for
AN13762 resistance were not resistant to other antimalarials, suggesting novel mecha-
nisms of action and resistance for AN13762, a valuable feature for a new class of anti-
malarial drugs.
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Malaria remains the most important parasitic disease in the world. In 2017, anestimated 219 million illnesses and 435,000 deaths were caused by malaria
parasites, mostly Plasmodium falciparum (1). Although the malaria burden decreased
considerably in the early 21st century, the decline appears to have stalled in recent
years. Major challenges to malaria control include resistance to all major classes of
antimalarials, including widely used artemisinin-based combination therapies (2).
Therefore, there is an urgent need for new antimalarial drugs, ideally with novel
mechanisms of action.
Benzoxaboroles have shown potent activity against a wide range of infectious
pathogens, including bacteria (3, 4), fungi (5), and protozoans (6–9). The highly elec-
trophilic nature of the boron component of these compounds leads to interaction with
a variety of protein targets (10, 11). Enzymes targeted in other systems have included
leucyl-tRNA synthetase (4, 5), phosphodiesterase 4 (12), kinases (13), and -lactamase
(14). Previously studied benzoxaboroles with potent antimalarial activity have been
shown to target leucyl-tRNA synthetase (8) and a cleavage and polyadenylation spec-
ificity factor (CPSF) homolog (15). CPSF homologs have also been the targets of
benzoxaboroles acting against the protozoan pathogens Toxoplasma gondii (16) and
Trypanosoma brucei (17, 18).
A robust pipeline of new antimalarial compounds is under development, and it is
important to explore many chemical families (19). For active compounds with drug-like
properties, it is very helpful to understand mechanisms of action and resistance. A
valuable means of characterizing mechanisms is to study P. falciparum selected for
resistance to compounds of interest (20). This report concerns characterization of
mechanisms for AN13762, a benzoxaborole that was declared a preclinical candidate in
2017 but that was later withdrawn due to unexplained toxicity in animal trials. AN13762
remains a valuable compound for exploring mechanisms of action and resistance of
antimalarial oxaboroles. Indeed, the compound appears to have a novel mechanism of
antimalarial action and multiple mechanisms of resistance selected by increasing
concentrations of the compound.
RESULTS
Antimalarial activity of AN13762 and related benzoxaboroles. AN13762 was
identified from a lead optimization program informed by the characterization of other
benzoxaboroles and focused on achieving a single-dose treatment for falciparum
malaria (8, 15, 21–23). AN13762 demonstrated rapid, nanomolar in vitro activity against
multiple strains of P. falciparum, potent activity against Plasmodium berghei and P.
falciparum in murine models, pharmacokinetics and bioavailability suggesting cure
after a single oral dose, and acceptable safety signals to warrant establishment as a
preclinical candidate by the Medicines for Malaria Venture (21). AN13762 and structur-
ally related benzoxaboroles demonstrated similar potencies against laboratory strains
and fresh Ugandan isolates of P. falciparum (Fig. 1). AN13762 was most active against
ring- and trophozoite-stage parasites. Parasites treated with AN13762 had abnormal
trophozoite morphology and did not develop beyond this stage.
Selection and analysis of parasites resistant to AN13762 and related benzoxa-
boroles. To gain insights into mechanisms of action and resistance, we cultured P.
falciparum with AN13762 to select, in a single step or stepwise manner, for parasites
with decreased sensitivity. For several independent single-step selections, parasites
were initially undetectable on Giemsa-stained smears, followed by regrowth. With 100
to 200 nM AN13762, parasites regrew after 18 to 39 days; with greater concentrations,
regrowth occurred more slowly (Fig. 2A). In stepwise selections, greater degrees of
resistance were also selected more slowly (Fig. 2B). Genomic DNA was extracted from
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parasites after each step of selection and analyzed by whole-genome sequencing. All
sequence data are described in Data Sets S1 and S2 in the supplemental material.
Notably, all parasites selected for decreased sensitivity to AN13762 contained single-
nucleotide polymorphisms (SNPs) in PF3D7_0709700, which encodes a lysophospho-
lipase homolog recently named prodrug activation and resistance esterase (PfPARE)
due to its demonstrated activation of antimalarial esters (24). Parasites with multiple
different PfPARE SNPs, including nonsense mutations, were selected (Fig. 2D). After
additional selection with higher concentrations of AN13762, most parasites contained,
in addition to PfPARE mutations, SNPs in enzymes predicted to function within ubiq-
uitination or sumoylation pathways, specifically, SUMO-activating enzyme subunit 2
(PfUba2; Pf3D7123700, lines A3 to A5), E3 SUMO ligase (Pf3D71360700, line J3), ring
zinc finger E3 ubiquitin ligase (Pf3D7_0529900, line F2), and ubiquitin-activating en-
zyme 1 (Pf3D71350400, line H2). Two lines selected for very high-level resistance (A5
and M3) contained SNPs in a P. falciparum CPSF homolog (PfCPSF3) which was recently
shown to be the target of another oxaborole antimalarial, AN3661 (15) (Fig. 2B).
AN13762-resistant parasites did not demonstrate copy number amplification for any
genes. After selection with AN13762, Dd2 and 3D7 lines with medium- to high-level
resistance (A2 to A4, J2, and J3) were cultured without drug pressure. In each case,
parasites cultured without drug pressure for 3 months had a stable phenotype, without
notable change in sensitivity to AN13762 (Fig. S1).
Parasites were also selected for resistance to structural analogs of AN13762 with
stepwise increases in concentrations of the compounds (Fig. 2C). For selection with
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Compounds 3D7 W2 Dd2 7G8 VS1 K1 D6
AN13762 42±4.6 18±1.6 52±4.0 69±7.8 73±2.0 103±5.1 118±5.3
AN13956 52±2.0 20±2.0 49±1.6 69±5.3 81±3.0 54±4.3 96±5.0 
AN10248 44±3.6 11±1.7 107±4.6 10±2.0 26±3.0 33±2.0 103±2.3
AN11063 490±14.9 208±3.6 430±4.2 1062±2.6 280±2.6 306±1.5 1129±4.7
FIG 1 In vitro activity of benzoxaboroles against P. falciparum. (A) Chemical structures of benzoxaboroles. (B) Sensitivity of laboratory strains to
benzoxaboroles. Values shown are mean IC50s  standard deviation based on 3 independent assays per strain, each performed in triplicate. (C)
Sensitivity of fresh P. falciparum isolates, collected in Tororo, Uganda, from 2016 to 2017, to benzoxaboroles. Each point represents a single
assessment for a clinical isolate or control laboratory strain. Mean values and standard deviation are shown in red. (D) Stage specificity of action
of AN13762. P. falciparum Dd2 was incubated with 0.5 M AN13762, 1.3 M chloroquine (each 10 the IC50), or 0.1% DMSO for 8-h intervals
across the life cycle and then continued in culture until the following ring stage, when parasitemias were counted and compared. Error bars
represent standard deviations from 3 independent experiments. (E) Morphology of parasites treated with 0.5 M AN13762. Photomicrographs
represent parasites treated with AN13762, beginning at the early ring stage, and untreated controls. ER, early ring; LR, late ring; ET, MT, and LT,
early, midstage, and late trophozoites, respectively; S, schizonts; h, hours.
Plasmodium falciparum Resistance to Benzoxaboroles ®
January/February 2020 Volume 11 Issue 1 e02640-19 mbio.asm.org 3
AB
C
D
Background Strain Dd2 3D7 W2
Selection Name A1 B1 C1 D1 E1 F1 G1 H1 I1 J1 K1 L1 M1
Drug Selection Concentration (µM) 0.1 0.1 0.16 0.2 0.2 0.2 0.2 0.2 0.16 0.2 0.2 0.4 0.3
Day of Recrudescence 18 18 22 36 33 36 35 31 21 39 35 56 45
0.18 0.18 0.28 0.42 0.82 0.63 0.52 0.72 0.32 0.82 0.89 1.34 1.25
Mutations in PfPARE L82* L82* L82* G206* P344L G51D R21* ND G206E G58C G58C A283D S94R
Background Strain Dd2 Dd2 Dd2 3D7 W2
Selection Name A1 A2 A3 A4 A5 F1 F2 H1 H2 J1 J2 J3 M1 M2 M3
Drug Selection Concentration (µM) 0.1 0.4 3.0 5.0 10.0 0.2 2.0 0.2 1.0 0.2 1.0 4.0 0.3 1.5 3.5
Day of Recrudescence 8 62 46 52 60 38 65 25 55 39 30 40 45 26 36
0.18 1.1 2.2 3.1 5.0 0.45 3.4 0.75 1.8 0.8 1.8 4.3 0.56 2.4 4.3
G
en
es
w
ith
m
ut
at
io
ns
PfPARE L82* L82* L82* L82* L82* G51D G51D ND K226* G58C M1I G58C S94R S94R S94R
PfUba2 - - Q62L Q62L Q62L - - - - - H184D - - - -
E3 SUMO Ligase - - - - - - -
-
- - - - I436K - - -
Ubiquitin Activating Enzyme 1 - - - - - - - - - - - - -
Ring E3 Ubiquitin Ligase - - - - - - --C236F - - - - - -
CPSF3 - - - - G289C - - - - - - - - - Y408N
Compound Name AN13956 AN11063 AN10248 AN3661
Background Strain Dd2 Dd2 Dd23D7 W2
Selection Name N1 N2 N3 O1 O2 O3 T1 U1 V1R1 R2 W3 W4
Drug Selection Concentration (µM) 0.25 2.0 4.0 0.6 3.0 6.0 0.14 0.2 0.30.1 0.4 1.0 5.0
Day of Recrudescence 50 65 50 32 45 40 32 45 none 90 73
1.0 2.0 5.6 0.97 5.4 7.7 - - -0.24 0.88 0.64 5.7
G
en
es
w
ith
m
ut
at
io
ns
PfPARE H304Y S195* S195* - - - - - -- - - -
Putative metallohydrolase - - - E784G E784G E784G - - -- - - -
E3 SUMO Ligase - - - - P431S P431S - - -- - - -
CPSF3 - - S444C - - - - - -- - D470N D470N
H36Y
PF3D7_0819000 - - - - - - - - -N346Y N346Y - -
PF3D7_0418000 - - - - - - - - -K3634R K3634R - -
Single step selections with AN13762
Stepwise selections with AN13762
Stepwise selections with other benzoxaboroles
M1I R21* G51D
G58C
L82* G206E/*
K226*S195*
G177V P241* H304Y
A283DS94R
F105I P344L
amino acid # 1 100 200 300 368
Hydrolase domain
IC50 (µM)
IC50 (µM)
IC50 (µM)
T300I
FIG 2 Schematics showing resistance selections and SNPs identified in selected parasites (shaded). Stop codons are indicated by asterisks. (A) Single-step
selections with AN13762 for indicated strains. We observed no dominant mutation (60% mutant reads at position) in strains D1, E1, F1, and G1. Upon closer
examination, several low-prevalence (20 to 50%) mutations were identified in PfPARE, with the most abundant mutation noted (Data Set S1). (B) Stepwise
selection with AN13762. In strain H2, a single nucleotide insertion (435529_435530) and subsequent frameshift leading to a premature stop codon was
observed. (C) Stepwise selection with other benzoxaboroles. For selections T1, U1, and V1, parasites did not recrudesce over 90 days. The results for
AN3661-resistant strains W3 and W4 were published previously (Sonoiki et al. [15]). (D) Map of nonsynonymous mutations selected in PfPARE.
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AN13956, low-level-resistant lines (N1 and N2) had SNPs in PfPARE, and lines selected
for higher-level resistance (N3) had an additional SNP in PfCPSF3, as observed for some
lines selected with AN13762. For selection with AN11063, low-level-resistant parasites
(O1) did not have SNPs in PfPARE but rather in a putative metallo-hydrolase. Parasites
with higher-level resistance to AN11063 (O2 and O3) had an SNP in E3 SUMO ligase
(Pf3D71360700) (Fig. 2C); another mutation in this gene was selected by AN13762 (J3).
For selection with AN10248, Dd2 strain parasites did not emerge after incubation for 60
to 90 days with 140 to 300 nM compound. However, 3D7 strain parasites were selected
for modest resistance after incubation with 100 nM AN10248 for 33 days and then
400 nM AN10248 for 28 days. Sequencing of the AN10248-resistant parasites revealed
SNPs in two P. falciparum genes predicted to encode proteins of unknown function
(PF3D7_0819000 and PF3D7_0418000). Copy number amplification was not detected
for any parasites selected for resistance to AN13956, AN11063, or AN10248.
PfPARE sequences of laboratory and field strains of P. falciparum. In laboratory
isolates, the PfPARE sequences are identical for the 3D7, Dd2, and 7G8 strains, except
for the S238I polymorphism in 7G8. For field isolates, we sequenced PfPARE from 12
Ugandan isolates, 3 with relatively low (50 nM), 5 with moderate (50 to 100 nM), and
4 with high (100 nM) IC50s. Four SNPs were seen in these isolates, M158I, K340R,
V420I, and T438A, the first in 10 isolates, and the others in 1 to 2 each, either as pure
or mixed populations. For the common M158I mutation, the two isolates with wild-type
(WT) sequences were two of three with relatively low IC50s, possibly identifying this
mutation as a mediator of sensitivity to AN13762. None of the identified mutations in
laboratory or field strains were those selected by culture with AN13762 (Fig. 2).
Mutations in PfPARE mediate AN13762 resistance. Interestingly, PfPARE muta-
tions have previously been reported to confer resistance in P. falciparum to antimalarial
esters, both a series of pepstatin esters and MMV011438, presumably due to a require-
ment for esterase activity of PfPARE for antimalarial activity (24). Although AN13762 is
not an ester, our characterization of resistant parasites suggested that this compound
also requires activation by PfPARE for maximal activity. Consistent with this hypothesis,
parasites selected for resistance to AN13762 were also resistant to pepstatin methyl
ester and MMV011438 (Fig. 3). To further test the hypothesis that mutations in PfPARE
mediate resistance to AN13762, we used CRISPR-Cas9 editing to engineer 3D7 and Dd2
parasites with the G58C or L82* PfPARE mutation (Fig. 4A). All transfectants demon-
strated 100% editing efficiency at the appropriate sites, including engineered silent
mutations at the single-guide RNA (sgRNA)-directed Cas9 binding sites. The PfPARE
G58C and L82* mutations conferred a 10 to 30-fold decrease in AN13762 sensitivity,
similar to changes in sensitivity in parasites that acquired these mutations after in vitro
resistance selection (Fig. 4F). These results confirm a primary role for PfPARE mutations
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in conferring resistance to AN13762 and suggest that PfPARE-mediated activation of
AN13762 is required for maximal antiparasitic activity.
A mutation in PfUba2 mediates high-level AN13762 resistance. Sequencing of
parasites selected for high-level resistance to AN13762 identified both 3D7 and Dd2
strain parasites with mutations in PfUba2. To confirm that PfUba2 mutations mediate
AN13762 resistance, we used CRISPR-Cas9 editing to engineer 3D7, Dd2, and PfPARE
L82* parasites with the Q62L PfUba2 mutation (Fig. 4B). All transfectants demonstrated
100% editing efficiency at the appropriate sites, including engineered silent mutations
at the sgRNA-directed Cas9 binding sites. In the engineered parasites, PfUba2 Q62L
conferred a 30- to 60-fold decrease in AN13762 sensitivity (Fig. 4F). Transfectants that
harbored both PfPARE L82* and PfUba2 Q62L mutations had an additional 40-fold
decrease in AN13762 sensitivity, similar to sensitivities of parasites (lines A3 and A4)
selected stepwise for high-level resistance and containing both of these mutations
(Fig. 2B). These results confirm that PfUba2 mutations confer AN13762 resistance and
that PfPARE and PfUba2 mutations have additive impacts on sensitivity to the com-
pound.
PfPARE processing of AN13762 is required for maximal antimalarial activity.
The results described above suggest that AN13762 is activated in parasites to a more
active metabolite by PfPARE. To test this hypothesis, we expressed recombinant PfPARE
in Escherichia coli. Recombinant PfPARE demonstrated esterase activity, with hydrolysis
of p-nitrophenyl butyrate (PNPB) to free p-nitrophenol (PNP) (Fig. S2). When recombi-
nant PfPARE was incubated with AN13762, we observed formation of AN10248
(Fig. 5A). Thus, PfPARE hydrolyzes AN13762 intracellularly to the active antimalarial
AN10248, and loss of the ability to activate the parent compound leads to decreased
AN13762 sensitivity. Of interest, PfPARE mutations that led to decreased sensitivity to
AN13762 did not notably alter sensitivity to AN10248 (Fig. 5B).
AN13762 appears to exhibit a novel antimalarial mechanism. Selection for
AN13762 resistance identified complex resistance mechanisms but did not clearly point
to a biochemical target. To gain insight into mechanisms of action, we assessed
cross-resistance between AN13762, related compounds, other benzoxaboroles with
known antimalarial mechanisms, and a panel of standard antimalarial drugs. Parasites
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selected for moderate resistance to AN13762 did not have markedly altered sensitivity
to any of a panel of 8 standard antimalarial drugs (Fig. 6A) or to other benzoxaboroles,
including those known to target P. falciparum PfCPSF3 (AN3661) (15) and leucyl-tRNA
synthetase (AN6426) (8) (Fig. 6B). Cross-resistance was seen between AN13762 and
AN13956. We then compared the sensitivities of parasites selected independently for
resistance to 5 different benzoxaboroles. For parasites selected for moderate resistance,
cross-resistance was seen between AN13762 and AN13956 and between AN3661 and
AN11063 (Fig. 7A). Considering parasites selected for higher levels of resistance,
cross-resistance was seen consistently between AN13762 and AN13956 at all levels of
resistance, between AN13762 and AN11063 with some, but not other, mutations, and
between AN13762, AN13956, and AN3661 for parasites selected for mutations in
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FIG 6 Sensitivities of wild-type and benzoxaborole-resistant parasites. (A and B) Sensitivities of wild-type parasites and those selected for
resistance to AN13762 are shown for standard antimalarials (A) and benzoxaboroles (B). Error bars represent standard deviations of the
results from 3 independent experiments. DHA, dihydroartemisinin.
 
 
 
  
  Mutations in specified genes  Compounds and mechanisms of action/resistance 
Strain 
 
PfPARE Ub-related genes CPSF3 
 AN13762 AN13956 AN10248 AN3661 AN11063 AN6426 
  Resistance mediated by 
PfPARE 
AN13762 
metabolite 
Targets 
CPSF3 
unknown Targets tRNA 
synthetase 
Wild type  - - -  69 74 98 86 674 255 
AN13762 A1  L82* - -  346 478 81 57 627 212 
A3  L82* Q62L (PfUba2) -  4908 4368 135 115 3481 239 
F2  G51D T300I (Ring Ub E3 ligase) -  2872 2753 127 59 1882 321 
H2  C206* C236F (Ub activating Enzyme 1) -  2643 2554 136 64 1677 364 
A5  L82* Q62L (PfUba2) G289C  10586 11208 230 4859 2785 342 
M3  S94R - Y408N  5134 4312 78 4913 379 290 
AN13956 N3  S195* - S444C  4658 4321 208 971 511 267 
AN11063 O3  - E3 Sumo Ligase -  274 401 81 384 7788 369 
AN3661 W3  - - D470N  72 60 98 451 3481 368 
AN10248 R2  - - -  227 203 886 82 690 272 
Strain AN13762 AN13956 AN10248 AN3661 AN11063 AN6426 
Wild type 67 58 71 35 511 234 
AN13762 A1 346 478 81 57 627 212 
AN13956 N1 463 395 78 29 478 267 
AN11063 O1 74 79 81 384 1102 369 
AN3661 W1 72 60 98 451 3481 317 
AN10248 R1 213 203 510 51 617 212 
B
A
FIG 7 (A and B) Sensitivities (IC50, in nanomolar) of low-level (A) and high-level (B) benzoxaborole-resistant parasites to all tested
benzoxaboroles. Ub, ubiquitin.
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PfCPSF3 (Fig. 7B). Cross-resistance was consistent with the selection of parasite geno-
types. Parasites selected for resistance to AN10248, the active metabolite of AN13762,
were not cross-resistant with any other compounds, and parasites selected for resis-
tance to 5 other benzoxaboroles were not resistant to the leucyl-tRNA synthetase
inhibitor AN6426.
We also compared the sensitivities of wild-type 3D7 strain parasites and those
selected for resistance to AN13762 to the components of the MMV Malaria Box (387
compounds) and Pathogen Box (127 compounds), collections of compounds previously
shown to be active against P. falciparum or other pathogens (https://www.mmv.org/
mmv-open/pathogen-box) (25). In screening with 3 the IC50 for each compound, only
one compound showed cross-resistance with AN13762-resistant strains A2 and J2 (Data
Set S3). This compound was MMV011438, the antimalarial ester for which selection of
resistance was accompanied by mutations in PfPARE (24).
DISCUSSION
Benzoxaboroles have shown promising antimalarial activity, with different benzo-
xaboroles acting against different P. falciparum targets (8, 15). Most recently, AN13762
demonstrated improved drug-like properties compared to other benzoxaboroles, in-
cluding excellent in vitro and in vivo potency against P. falciparum, leading to its
declaration as a preclinical candidate by the Medicines for Malaria Venture (21).
Although development of the compound was later halted due to unexplained animal
toxicity, it remains of interest for the characterization of antimalarial mechanisms of
action and resistance. Selection and characterization of P. falciparum with decreased
sensitivity to AN13762 identified a complex mechanism of resistance, with loss of
function of PfPARE associated with low-level resistance, and mutations in five other
proteins, most participating in ubiquitin/sumoylation enzyme cascades, associated with
high-level resistance. These selections did not identify a single P. falciparum target for
AN13762, but cross-resistance studies suggested a mechanism of action unique from
that of other studied benzoxaboroles.
The characterization of sequences of P. falciparum selected for resistance in vitro has
offered valuable insights into mechanisms of action and resistance, including the
identification of dozens of independent targets for recently characterized antimalarial
compounds (20). In the case of benzoxaboroles, studies showed AN6426 and AN8432
to target P. falciparum leucyl-tRNA synthetase (8) and AN3661 to target PfCPSF3, a
homolog of a component of the mammalian CPSF complex (15). We embarked on a
similar strategy to characterize mechanisms for AN13762. Midnanomolar concentra-
tions of AN13762 readily selected for parasites with low-level resistance (midnanomolar
IC50s against cultured parasites). Higher-level resistance (micromolar IC50s) was subse-
quently selected by micromolar concentrations of AN13762, although longer-duration
incubations were required to select high-level resistance.
Parasites selected for low-level resistance to AN13762 consistently contained any of
a number of mutations, including null mutations, in PfPARE, a lysophospholipase
homolog for which mutations were also recently shown to mediate resistance to the
antimalarial compound MMV011438 and a series of pepstatin esters (24). Incubation of
P. falciparum with MMV011438 and pepstatin butyl ester selected for mutations in
PfPARE, and it was shown that PfPARE acted as an esterase to activate these com-
pounds. AN13762 is not an ester, and this parent compound has potent activity, but our
results suggest that it too requires activation by PfPARE for maximal antimalarial effects.
Specifically, we demonstrated that recombinant PfPARE hydrolyzed AN13762 to
AN10248, a compound that is also a potent antimalarial, and that introduction of a
PfPARE null mutation yielded similar levels of resistance to those in parasites selected
with midnanomolar concentrations of AN13762. Taken together, our results strongly
suggest that intracellular hydrolysis of AN13762 to AN10248 by PfPARE is required for
full activity. We hypothesize that intracellular access of AN10248, a carboxylic acid, is
limited, and that intracellular activation of AN13762 to AN10248 enables a more potent
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antimalarial effect. Other benzoxaboroles similarly showed antitrypanosomal activity
based on intracellular activation of prodrugs (26).
Additional insight into resistance mechanisms was gained by selecting for higher-
level resistance with micromolar concentrations of AN13762. These selections yielded
parasites with high-level resistance (IC50s of 1 M against cultured parasites). These
resistant parasites contained PfPARE mutations plus additional mutations in any of 5
different genes. Interestingly, 4 of the additional genes mutated in highly resistant
parasites encode components of P. falciparum ubiquitin or sumoylation cascades. More
specifically, SUMO-activating enzyme subunit 2 was mutated in resistant 3D7 and Dd2
strain P. falciparum, with IC50s of 2.2 M or higher, E3 SUMO ligase was mutated in 3D7
strain parasites, with an IC50 of 4.3 M, ubiquitin-activating enzyme 1 was mutated in
Dd2 strain parasites, with an IC50 of 1.8 M, and E3 ubiquitin ligase was mutated in Dd2
strain parasites, with an IC50 of 3.4 M. CRISPR-Cas9-mediated introduction of PfPARE
and PfUba2 mutations recapitulated resistance to AN13762, confirming their mediation
of altered parasite sensitivity. Mutations in PfPARE and PfUba2 had additive effects in
conferring resistance to AN13762, with the degree of resistance similar in double
mutants either engineered by CRISPR-Cas9 mutagenesis (3.7 M) or selected by culture
with stepwise increasing concentrations of AN13762 (2.2 to 3.1 M).
Ubiquitination and sumoylation pathways participate in posttranslational modifica-
tions to label proteins for proteasomal degradation and regulate a range of cellular
processes, and both pathways participate in cellular stress responses. In P. falciparum,
ubiquitination (27) and sumoylation (28, 29) appear to serve as important regulators of
stress responses. The stress response engendered by treatment with artemisinins
includes an accumulation of ubiquitinated proteins (30). Synergism was seen between
artemisinins and proteasome inhibitors, supporting the P. falciparum stress response as
a target for artemisinins. Accumulation of ubiquitinated proteins was diminished in
artemisinin-resistant parasites, suggesting an enhanced stress response in resistant
parasites (30). Our results showed that high-level resistance to AN13762 was associated
with mutations predicted to disrupt the ubiquitination and sumoylation systems,
suggesting that, in contrast to results with artemisinins, a diminished stress response
facilitated drug resistance. Presumably, AN13762 exerts antimalarial activity in part by
augmenting stress responses, and alterations in these responses, via mutations in at
least 4 different ubiquitination/sumoylation enzymes, enable high-level drug resis-
tance. These results further indicate that mutations altering ubiquitination/sumoylation
enzymes are tolerated by malaria parasites. Some of these mutant parasites were
shown to be stable in culture without drug pressure, but the overall impacts of the
mutations on parasite fitness are not known.
Resistance to the related benzoxaborole AN11063 was associated with a mutation in
a predicted metallo-hydrolase. In a situation analogous to that for AN13762, low-level
resistance (IC50, 0.98 M) to AN11063 was associated with the metallo-hydrolase
mutation, and higher-level resistance was associated with the addition of a mutation in
E3 SUMO ligase (IC50, 5.4 M). We hypothesize that the metallo-hydrolase metabolizes
AN11063 to a more potent intracellular compound, as is the case with PfPARE and
AN13762. Interestingly, resistance to AN10248, the active metabolite of AN13762, was
not readily selected, although for 3D7 (but not Dd2) parasites, resistant strains with
mutations in two poorly annotated parasite genes were identified.
Some selections of high-level resistance to both AN13762 (IC50, 4.3 M in W2 strain
parasites) and AN13956 (IC50, 5.6 M in Dd2 strain parasites) were accompanied by
mutations in both PfPARE and PfCPSF3. PfCPSF3 is a homolog of a component of the
mammalian CPSF complex, which is required for maturation of mRNAs, and was
discovered after another benzoxaborole, AN3661, selected for mutations in this protein
(15). PfCPSF3 was shown to be the P. falciparum target for AN3661, as incubation with
the compound led to loss of transcripts for trophozoite proteins in treated wild-type
parasites, as expected with loss of CPSF activity, but not in treated mutant parasites.
Our new results indicating that high-level resistance to AN13762 and AN13956 can also
be accompanied by mutations in PfCPSF3 suggest that this protein is also a target for
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these other benzoxaboroles. However, selection of PfCPSF3 mutations only in highly
resistant parasites and the lack of cross-resistance between AN13762 and AN3661
(except for highly resistant parasites with PfCPSF3 mutations) suggest that PfCPSF3 is
not the primary target of AN13762. Taken together, our results from prior studies (8, 15)
and those reported here suggest that benzoxaboroles target multiple proteins in P.
falciparum, complicating drug discovery for this class of antimalarials.
Our study has important limitations. First, it is not clear that the multiple mutations
identified as contributing to resistance fully explain the activity of AN13762. It is
noteworthy that activity against laboratory and field strains varied quite widely; this
variation is not fully explained by the identified mutations. Second, although our
genetic evidence was solid and we showed hydrolysis of AN13762 to AN10248 in vitro,
technical challenges limited our ability to biochemically confirm this metabolism in
intact parasites. Specifically, we were unable to detect AN10248 in cultured parasites
treated with AN13762. Third, although we identified mutations in multiple genes that
encode members of ubiquitination and sumoylation pathways in resistant parasites, we
were unable to identify changes in ubiquitination or sumoylation in the mutant
parasites. Fourth, although metabolism by PfPARE of AN13762 to AN10248 was re-
quired for full activity, the two compounds had similar antimalarial activities; we predict
that AN10248 has better access to intracellular drug targets, but this has not been
proven.
Consideration of cross-resistance in parasites selected for resistance to benzoxa-
boroles was informative. AN13762 and AN13956 were cross-resistant, consistent with
shared mechanisms of action. Cross-resistance was not seen between AN13762 and
other benzoxaboroles known to target leucyl-tRNA-synthetase. Cross-resistance was
seen with AN3661, which targets PfCPSF3, but only with highly resistant parasites that
had mutated PfCPSF3. AN13762 was also not cross-resistant with standard antimalar-
ials, with similar activities against parasites sensitive or resistant to chloroquine and
with minimal differences in activities of 8 tested antimalarials against parasites sensitive
or highly resistant to AN13762. Further, in a screen of 514 compounds included in the
MMV Malaria Box and Pathogen Box, the only compound that showed clear cross-
resistance with AN13762 was MMV011438, the ester that, as explained above, also
selects for resistance via mutation of PfPARE. Taken together, these results suggest a
unique set of mechanisms of resistance and quite likely a novel antimalarial mechanism
of action for AN13762 and closely related benzoxaboroles.
MATERIALS AND METHODS
Culture of malarial parasites. Human red blood cells infected with P. falciparum were cultured
using standard methods at 2% hematocrit in RPMI 1640 medium (Invitrogen) supplemented with 0.5%
AlbuMAX II (Gibco Life Technologies), 2 mM L-glutamine, 100 mM hypoxanthine, 5 g/ml gentamicin,
28 mM NaHCO3, and 25 mM HEPES at 37°C in an atmosphere of 5% O2, 5% CO2, and 90% N2. P. falciparum
strains were obtained from the Malaria Research and Reference Reagent Resource Center, Manassas,
Virginia.
Activity against cultured laboratory strains of P. falciparum. The studied benzoxaboroles were
analyzed by nuclear magnetic resonance, liquid chromatography-mass spectrometry, and high-
performance liquid chromatography for structural characterization and purity. The studied antimalarials
were from Sigma-Aldrich, except for piperaquine, which was from Jinan Jiaquan International Trade Co.
Pepstatin methyl ester was from EMD Millipore, and MMV011438 was a gift from Daniel Goldberg.
Parasites were synchronized by treatment with 5% D-sorbitol and cultured in triplicate 96-well culture
plates (200 l per well) with serially diluted compounds at concentrations of 1 nM to 10 M, with a total
of 8 concentrations tested for each compound, and final dilutions containing 0.2% dimethyl sulfoxide
(DMSO). Compounds from the MMV Malaria Box (387 compounds, a gift from Robert St. Onge) and
Pathogen Box (127 compounds, acquired from MMV) were screened against 3D7 and Dd2 strain parasites
and strains selected for resistance to AN13762 (A2 and J2) at 3 the IC50, determined against the
wild-type strains; AN13762 was included as a control. After 48 h of incubation with test compounds,
cultures were fixed with 2% formaldehyde for 24 h at 37°C or 48 h at room temperature, cells were
stained with 4 nM YOYO-1 dye (Molecular Probes), and the counts of treated and control cultures were
determined with a fluorescence-activated cell sorter. IC50s were calculated by nonlinear regression using
the GraphPad Prism software.
Activity against fresh P. falciparum field isolates. The activities of benzoxaboroles were tested
against fresh P. falciparum isolates using a 72-h growth inhibition assay with Sybr green detection, as
previously described (31). Isolates were collected from March 2016 to July 2017 from patients in the
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Tororo and Busia Districts, Uganda, who were newly diagnosed with P. falciparum malaria; samples were
collected before antimalarial treatment was administered. The relevant clinical trials (registered at
ClinicalTrials.gov no. NCT02163447) and analyses of cultured parasites were approved by the Uganda
National Council of Science and Technology, the Makerere University Research and Ethics Committee,
and the University of California, San Francisco Committee on Human Research. Informed consent was
obtained from blood donors or their parents/guardians.
Stage specificity and morphological effects of AN13762. The stage-specific activities of AN13762
and chloroquine were analyzed as previously described (32). Highly synchronous Dd2 P. falciparum cells
(synchronized by treatment with 5% D-sorbitol) were cultured in triplicate in 96-well culture plates with
500 nM AN13762 or 1.3 M chloroquine for 8-h intervals, beginning at the ring stage; each culture was
incubated with the test compound for only one 8-h interval within the parasite life cycle. Control cultures
contained equivalent concentrations of DMSO (0.2%). At the end of each interval, the cultures were
washed three times and resuspended in culture medium without drug. After 48 h, when control parasites
were at the ring stage, the cultures were fixed with 2% formaldehyde and counted using flow cytometry,
as detailed above, and parasitemias were compared with those of untreated control parasites. Giemsa-
stained smears of parasites incubated with AN13762 for different intervals were examined microscopi-
cally and photographed.
Selection of parasites with decreased sensitivity to benzoxaboroles. Triplicate 10-ml cultures of
3D7, Dd2, and W2 strains of P. falciparum, each containing a clonal population of 6 107 asynchronous
parasites, were incubated with benzoxaboroles. In single-step selections, parasites were incubated with
100 to 400 nM compound. In stepwise selections, parasites were incubated with increasing concentra-
tions, as outlined in Fig. 2. In all selections, cultures were monitored with Giemsa-stained smears. At each
step of selection, parasites were initially undetectable, followed by regrowth. When parasites achieved
multiplication rates approximately equivalent to those of untreated controls, IC50s were determined, and
aliquots were frozen for long-term storage. For stepwise selections, parasites were incubated with
increased concentrations of compounds, as detailed in Fig. 2. Resistant strains A2, A3, and A4 were grown
without drug pressure for up to 90 days, with regular assessment of sensitivity to AN13762. Mutant
clones with altered sensitivity to test compounds will be made available to researchers through the
Malaria Research and Reference Reagent Resource Center (MR4) upon request.
Whole-genome sequencing. Genomic DNA was extracted from parasite cultures (10 ml at 2%
hematocrit and 10% parasitemia) using the PureLink genomic DNA kit (Invitrogen) and extracted per
manufacturer’s instructions. Paired-end next-generation sequencing libraries were constructed from the
genomic DNA (gDNA) using the NEBNext Ultra II kit (New England BioLabs). The gDNA (200 ng) was
enzymatically fragmented for 17.5 min at 37°C, and the reaction was quenched with EDTA. The samples
were cleaned with AMPure beads (Beckman Coulter) at a sample-to-bead ratio of 1:1.4 and eluted in
sterile H2O. Eluted samples were run on a Bioanalyzer high-sensitivity (HS) DNA kit (Agilent) to confirm
the presence of 200- to 300-bp gDNA fragments. Samples were then subjected to end prep and adaptor
ligation using a 1:10 dilution of the NEBNext adaptor, all as described in the NEBNext Ultra II protocol.
After digestion with the USER enzyme, a second AMPure bead cleanup was carried out with a
sample-to-bead ratio of 1:0.9 for 15 min prior to placing the beads on a magnet and eluting with sterile
H2O. Samples were then indexed with 9 cycles of PCR using NEB Q5 polymerase, unique TruSeq i5/i7
barcode primers, and conditions according to the NEB Q5 protocol. A final AMPure bead cleanup step
was performed at a sample-to-bead ratio of 1:0.9, with elution with sterile H2O. Library quality was
assessed with a Bioanalyzer HS DNA kit, with broad peaks from 200 to 500 bp observed in each sample,
as expected. Libraries were pooled and sequenced on an Illumina HiSeq 4000 platform using a PE100
(paired end 100 base pair) flow cell.
Sequence analysis. After demultiplexing, fastq files were filtered with PriceSeqFilter (33) with the
flags “-rqf 100 0.99 -rnf 100,” specifying that in all reads, 100% of nucleotides must have a 99% chance
of being correct, and that no reads may contain any ambiguous characters. The filtered fastq files were
then aligned to the 3D7 genome from PlasmoDB, version 26 (34), using Bowtie2 (35), with the following
flags: “-p 20 –very-sensitive -x.” The resulting SAM files were imported into Geneious version 10.0.9 (36)
and run through MinorityReport to assess genetic differences (37). The aligned sequencing reads for
genes of interest were input along with the FASTA and GFF files for the 3D7 reference genome from
PlasmoDB, version 26 (34). The thresholding flags “-wtc 5,” “-vp 0.6,” and “-vc 5” were used, requiring each
reported variant to have a coverage of at least 5 reads in both the parent and the mutant and at least
60% of the mutant reads to contain the variant. Gene copy number variation analysis was performed to
calculate the ratio of reads that map to each sliding window in the mutant and parent data sets,
normalized by the total number of reads for the parent and mutant (37).
CRISPR-Cas9-mediated editing of PfPARE and PfUba2 mutations. Choice of sgRNA, plasmid
construction, and parasite transfections were performed as described previously (38). The primers used
for sgRNA and donor constructs are listed in Table S1. G58C and L82* mutations in PfPARE and the Q62L
mutation in PfUba2 were chosen for CRISPR-Cas9 engineering in wild-type parasites. sgRNAs were
inserted into a pDC2-cam-Cas9-U6-hdhfr plasmid that encodes Streptococcus pyogenes Cas9 expressed
under the calmodulin promoter and a human dihydrofolate reductase (dhfr) selectable marker (that
mediates resistance to the human dhfr inhibitor WR99210); the sgRNA was expressed with a U6
promoter. A 1.2-kb fragment of donor template was amplified from wild-type (3D7 and Dd2) and
AN13762-resistant (A2 and J2) strains containing the mutation of interest. Using the QuikChange
Lightning multisite-directed mutagenesis kit, 3 or 9 nucleotide substitutions were introduced into the
donor sequences at sgRNA-binding sites to protect from further Cas9 recognition and cleavage (binding
site mutations are detailed in Table S1). The resulting fragment was inserted using the ApaI and BamHI
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restriction sites into the pDC2-bsd plasmid, which expresses the blasticidin S-deaminase (bsd) selectable
marker. Each of the pDC2-PfPARE donor-bsd plasmids encoding PfPARE wild-type and G58C mutants was
transfected 2 times into Dd2 parasites and 2 times into 3D7 parasites by electroporation, along with the
pDC2-cam-Cas9-U6-sgRNA-hdhfr plasmid. Of those 4 transfections per plasmid, two were maintained in
2.5 nM WR99210 (Sigma-Aldrich) and 2 mg/ml blasticidin (Sigma-Aldrich), and another two were main-
tained in 150 nM AN13762. Similarly, transfections were carried out for PfUba2 mutant (Q62L) parasites
in 3D7 and Dd2 and in a 3D7 parasite carrying both the PfPARE (L82*) and PfUba2 (Q62L) mutations.
Transfections were performed in 400 l of 1 Cytomix containing 10% rings and 100 g of Cas9 and
donor plasmids per transfection. Electroporation was performed in a cuvette at 0.310 kV and 950 F.
Transfectants were maintained under standard culture conditions for 4 weeks, and then gDNA was
extracted. Fragments of PfPARE and PfUba2 were amplified from gDNA using Phusion high-fidelity DNA
polymerase (Thermo Scientific), and the primers are described in Table S1. The PCR conditions used were
98°C for 5 min; 30 cycles of 98°C for 10 s, 60°C for 20 s, and 72°C for 80 s; and 72°C for 5 min. The amplified
fragments were cleaned using AMPure beads (Beckman Coulter) and Sanger sequenced at Eurofins
Genomics. IC50 values were obtained for all transfectants using the methods described above.
Recombinant protein expression and esterase assay. The PfPARE gene (PF3D7_0709700) was
amplified from genomic P. falciparum DNA using the primers PfPARE-ExP-F and PfPARE-ExP-R (Table S1).
The gene was cloned into a pET-28b() plasmid between the NcoI and XhoI restriction sites with a
TaKaRa In-Fusion cloning kit to obtain recombinant protein, with a C-terminal His6 tag with a molecular
weight (MW) of 43,423 Da. The His-tagged PfPARE pET-28b construct was transformed into Rosetta
2(DE3) Singles E. coli competent cells (Novagen), and these cells were grown overnight and used to
inoculate fresh cultures, which were grown for 2 to 4 h to optical density 0.5 to 0.7 and induced with
0.5 mM isopropyl--D-thiogalactopyranoside (IPTG) for 6 h at 30°C. The bacterial pellet was then lysed by
sonication in 50 mM Tris-HCl (pH 8), 200 mM NaCl, 10% glycerol, 0.1% Triton X-100, and protease
inhibitor cocktail (Roche cOmplete tablet). Supernatant containing 10 mM imidazole was incubated with
2 ml of 50% nickel-nitrilotriacetic acid (Ni-NTA) agarose beads (Qiagen) with rotation for 1 h at 4°C. The
lysate was then allowed to flow through under gravity, and the column was washed twice with 25 ml of
20 mM imidazole. The recombinant His tag fusion protein was eluted with lysis buffer containing 250 mM
imidazole. For assays with PNPB, 0.1 mg of purified protein was incubated with 0 to 833 mM PNPB
(prepared as a 50 mM stock in acetonitrile) in phosphate-buffered saline (PBS) at 37°C, and reactions were
monitored for absorbance at 405 nm, indicating formation of PNP using a Tecan Infinite 200 Pro plate
reader.
LC-MS analysis. For assays analyzed by liquid chromatography-mass spectrometry (LC-MS), 0.1 mg
of protein was incubated for 48 h at 22°C with 20 nmol compound in a 100-l reaction mixture.
Heat-denatured enzyme was used as a negative control. The reaction mixture was filtered using an
Amicon Ultra centrifugal filter (0.5 ml, 3-kDa cutoff) to remove protein, and 20 to 50 l flowthrough was
injected on the LC-MS. The samples were analyzed on a Waters Micromass ZQ mass spectrometer
equipped with a Waters 2795 separation module, Waters 2424 evaporative light scattering detector, and
Waters 2996 photodiode array detector. Separations were carried out with an XTerra MS C18, 5-mm,
4.6- by 50-mm column at ambient temperature using a mobile phase of water-methanol containing a
constant 0.1% formic acid.
Data availability. The raw data have been deposited under NCBI Sequence Read Archive number
SRP228727 (https://trace.ncbi.nlm.nih.gov/Traces/sra/?studySRP228727) and BioProject number
PRJNA504044 (https://www.ncbi.nlm.nih.gov/bioproject/?termPRJNA504044). This represents the min-
imal underlying data set for this study.
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